# Meihua Bio (600873): Q3 2026 earnings pressured by lower product prices; high-end amino acids open a new growth curve

> Meihua Bio reported a 76.46% year-on-year decline in net profit for the first three quarters of 2026, while third-quarter profit fell 96%. Higher sales volumes were offset by lower prices for lysine and threonine; the company said growth in pharmaceutical-grade amino acids partly countered weaker revenue from its core products.

- Date: 2026-11-08 · published 2026-11-08T21:11:32.878Z
- Category: market · region China · magnitude medium
- Page: https://feedsoft.ai/events/88021-meihua-bio-600873-q3-2026-earnings-pressured-by-lower-product-prices-high-end
- Commodities: [Lysine](https://feedsoft.ai/c/LYSINE.md)

## Why it matters

Lower lysine prices and expanded production are adding supply pressure, weighing on lysine prices. The company expects core product prices to be near a floor, but that recovery has not yet materialized.

## Read by commodity

- LYSINE: bearish ▼

## Sources

- caijing.hzdx.com: http://www.caijing.hzdx.com/ziben/2026/1108/2153.html

---
Data from Feedsoft AI (https://feedsoft.ai/). For information only; not investment advice.